logo
logo

Newron Receives Fifth Tranche From Financing Agreement With European Investment Bank (Eib)

Oct 18, 2021over 3 years ago
Milan

Description

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received Tranche 5 under its financing agreement with the European Investment Bank (EIB) that was signed in October 2018 and comprises up to EUR 40 million, subject to achieving a set of agreed performance criteria. The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment plan for Europe. Tranche 5 consists of EUR 7.5 million and will primarily be used to support the Company’s development programs in diseases of the central nervous system

Company Information

Company

Newron Pharmaceuticals

Location

Milan, Lombardy, Italy

About

We are a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system

FundzWatch™ Score

85
Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood